Announcement on Sale of Equity in Holding Subsidiary
Filed with SSE · · 9 pages · Chinese
Summary by 6ix AI
The board approved the transaction, which does not require shareholder approval and is not classified as a related party transaction or a major asset restructuring. The sale aims to optimize the company's asset structure and enhance operational efficiency without adversely affecting its core business or financial results.
Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries
Thalys Medical Technology Group Inc. on 6ix
Earlier from Thalys Medical Technology
- Announcement on Completing Industrial and Commercial Change Registration and Obtaining Renewed Business License
- Announcement on Convening Performance Briefing for 2025 and Q1 2026
- Announcement on Resolutions of the 27th Meeting of the 5th Board of Directors
- Report for Q1 2026
- Announcement on Progress in Transferring Holding Subsidiary's Equity
Later from Thalys Medical Technology
- Announcement on Closing Investment Projects Financed by Raised Funds and Using Residual Raised Funds to Permanently Supplement Current Capital
- Announcement on Adding Extraordinary Proposal to the 2nd Extraordinary General Meeting in 2026
- Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2026
- Announcement on Reply to Letter of Supervision and Inquiry on Information Disclosure of 2025 Annual Report
- Announcement on Progress in Reduction of Repurchased Shares through Call Auction
Follow Thalys Medical Technology into a list and get an email when it puts out news.
Follow Thalys Medical Technology